Biological Gastroenterology

Rebyota

Payments companies reported to CMS as associated with Rebyota. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.3Massociated payments (2023-2025)

8,198clinicians with associated payments

6companies reporting

By year

2023 $1.7M

2024 $359K

2025 $220K

Payments reported as associated with Rebyota, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $1.3M

Infectious Disease $590K

Internal Medicine $124K

Family $96K

Physician Assistant $35K

Medical $35K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Rebyota

These are the largest totals companies reported as associated with Rebyota. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Paul Feuerstadt	Hamden, CT	Gastroenterology (Internal Medicine)	$326,752.97
Anurag Maheshwari	Baltimore, MD	Gastroenterology (Internal Medicine)	$115,082.14
Colleen Kraft	Atlanta, GA	Infectious Disease	$99,000.00
Carl Crawford	New York, NY	Gastroenterology (Internal Medicine)	$91,900.43
Sahil Khanna	Rochester, MN	Gastroenterology (Internal Medicine)	$77,790.51
Timothy Miller	Temple, TX	Internal Medicine	$72,300.85
Arthur Jeng	Sylmar, CA	Infectious Disease	$51,994.39
Ali Hassoun	Huntsville, AL	Infectious Disease	$44,729.57
Caterina Oneto Araya	New York, NY	Gastroenterology (Internal Medicine)	$38,406.74
Daniel Van Handel	Plymouth, MN	Gastroenterology (Internal Medicine)	$37,908.00

Prescribed Rebyota?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.